Acceleron  

Publications

  • Publication
    Mar 20, 2017
    Manifestations and Impact of Facioscapulohumeral Muscular Dystrophy (FSHD): Preliminary Results from a Survey of FSHD Patients. MDA Scientific Conference 2017; March 20th, 2017.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 5, 2016
    Luspatercept Increases Hemoglobin, Decreases Transfusion Burden, and Improves Patient-Reported Outcomes in Adults with Beta-Thalassemia
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. ASH 2016; December 6th, 2017.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results From Phase 2 Studies
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Beta-Thalassemia: Preliminary Results From Phase 2 Studies
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Dec 1, 2016
    A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer. December 1, 2016; 122(23):3641-3649
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Nov 11, 2016
    Luspatercept Posters at the 2016 TIF 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies; November 11-12, 2016
    + VIEW FULL Publication
  • Publication
    ACE-083
    Nov 10, 2016
    A Phase 2 study to evaluate ACE-083, a local muscle therapeutic, in patients with FSHD. FSH Society 2016 Research Connect Conference; November 10, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Oct 6, 2016
    A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. Patient-Centered Charcot-Marie-Tooth Summit; October 6, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Sep 9, 2016
    A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. 6th International CMTR Consortium Meeting; September 9, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Jul 8, 2016
    ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases; July 8, 2016.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 12, 2016
    Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 11, 2016
    Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Jun 10, 2016
    ACE-1332 Inhibits Elevated TGFβ1 Signaling and Reduces Fibrosis in a Murine Model of Myelofibrosis. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 10, 2016
    RAP-536 (Murine Analog of ACE-536/Luspatercept) Inhibits SMAD2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in a Murine Model of Beta-Thalassemia; 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 10, 2016
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low- Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE‐MDS Study; 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    ACE-083
    Apr 2, 2016
    ACE-083, a Locally-Acting TGF-Beta Superfamily Ligand Trap, Increases Muscle Volume of Targeted Muscle: Preliminary Results from a Phase 1 Dose Escalation Study in Healthy Volunteers. ENDO 2016; April 1-4, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Mar 21, 2016
    ACE-083, a locally-acting TGF-beta superfamily ligand trap, increases muscle volume of targeted muscle: Preliminary results from a Phase 1 dose escalation study in healthy volunteers. 2016 MDA Clinical Conference; March 20-23, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Mar 21, 2016
    ACE-083, a Locally-Acting TGF-β Superfamily Ligand Trap, Increases Muscle Mass and Strength in a Mouse Model of ALS. 2016 MDA Clinical Conference; March 20-23, 2016.
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 7, 2015
    Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    RAP-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in Murine β-Thalassemia. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    TGFβ1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 6, 2015
    Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 5, 2015
    Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. The 57th Annual American Society of Hematology; December...
    + VIEW FULL Publication
  • Publication
    ACE-083
    Dec 5, 2015
    Phase 1 dose escalation study of ACE-083 in healthy volunteers: Preliminary results for a locally acting muscle therapeutic. The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) Conference; December 2015.
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 6, 2015
    Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Subjects: Interim Analysis of a Phase 2 Study. The 48th Annual American Society of Nephrology Kidney Week; November 6, 2015.
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Nov 6, 2015
    The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium; November 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Nov 6, 2015
    The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium; November 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 5, 2015
    Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis. American Society of Nephrology Kidney Week 2015; November 5, 2015
    + VIEW FULL Publication
  • Publication
    ACE-083
    Oct 5, 2015
    Poster Presentation – A phase 1 dose escalation study of ACE-083, a locally-acting muscle therapeutic, in healthy volunteers. FSHD International Research Consortium; October 5, 2015
    + VIEW FULL Publication
  • Publication
    ACE-2494
    Oct 1, 2015
    ACE-2494, a Novel GDF Ligand Trap, Increases Muscle Mass Upon Systemic Administration in Mice. 20th International Congress of the World Muscle Society; October 1, 2015
    + VIEW FULL Publication
  • Publication
    ACE-083
    Oct 1, 2015
    ACE-083 Increases Muscle Hypertrophy and Strength in C57BL/6 Mice . 20th International Congress of the World Muscle Society; October 1, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Sep 18, 2015
    Sotatercept (ACE-011) for the Treatment of Chemotherapy-Induced Anemia in Patients with Metastatic Breast Cancer or Advanced or Metastatic Solid Tumors Treated with Platinum-Based Chemotherapeutic Regimens: Results from Two Phase 2 Studies. Supportive Care in Cancer 2015; published online Sept 14, ...
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 15, 2015
    Endothelial ALK1 is a Therapeutic Target for Impairing Metastatic Dissemination of Breast Cancer. Cancer Research June 15, 2015; 75(12):2445-2456
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 13, 2015
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk MDS: Preliminary Results from the Phase 2 PACE-MDS Study. 20th Congress of the European Hematology Association; June 13, 2015
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 12, 2015
    Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Liver Iron Concentration in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 20th Congress of the European Hematology Association; June 12, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 1, 2015
    Poster – The DART Study: Dalantercept Part 2. American Society of Clinical Oncology (ASCO) Annual Meeting. June 1, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 1, 2015
    Poster – The DART Study: Dalantercept Part 1. American Society of Clinical Oncology (ASCO) Annual Meeting. June 1, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 30, 2015
    Quantitative Computed Tomography Results for Bone Mass and Abdominal Aortic Vascular Calcification in Hemodialysis Subjects Treated With Escalating Dose Levels of Sotatercept: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress; May 30, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 29, 2015
    Long-term Effects of 3 Dose Levels of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress; May 29, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 29, 2015
    The Role of Activin Signaling in the Pathogenesis of Renal Osteodystrophy of CKD-MBD. 52nd ERA-EDTA Congress; May 29, 2015
    + VIEW FULL Publication
  • Publication
    Luspatercept
    May 2, 2015
    Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study. 13th International Symposium on Myelodysplastic Syndromes (MDS), May 2, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Apr 29, 2015
    Oral Presentation – A Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. 13th International Symposium on Myelodysplastic Syndromes (MDS)...
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 28, 2015
    Oral Presentation – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. February 28, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 28, 2015
    Poster – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. February 28, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jan 16, 2015
    The DASH STUDY: A Phase 1b Study of Dalantercept Plus Sorafenib in Advanced Hepatocelluar Carcinoma. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium. January 16, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 8, 2014
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results from a Phase 2 Study. 56th Annual American Society of Hematology Annual Meeting and Exposition; December 8, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 8, 2014
    Modified ActRIIB-mFc Fusion Protein Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease. 56th Annual American Society of Hematology Annual Meeting and Exposition; December 8, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 7, 2014
    An Open-Label, Phase 2, Dose-Finding Study of Sotatercept in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes or Non-Proliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion. 56th American Society of Hematology Annual Meeting and Exposition; December 7, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2014
    Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 56th American Society of Hematology Annual Meeting and Exposition; December 7, 2014.
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 13, 2014
    Safety and Hemoglobin Effect of the First 28-Day Dose Cycle of Sotatercept 0.7 mg/kg Compared With Lower Doses and Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis. American Society of Nephrology Kidney Week 2014; November 13, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 13, 2014
    Sotatercept: Results for Bone Mass and Vascular Calcification in Hemodialysis Subjects Treated With Escalating Doses: Interim Analysis of ACE-011-REN-001. American Society of Nephrology Kidney Week 2014; November 13, 2014
    + VIEW FULL Publication
  • Publication
    ACE-083
    Oct 9, 2014
    ACE-083, a Ligand Trap for Members of the TGF-β Superfamily, Increases Muscle Mass Locally in a Mouse Model of Duchenne Muscular Dystrophy . 19th International Congress of the World Muscle Society; October 9, 2014
    + VIEW FULL Publication
  • Publication
    ACE-083
    Jul 7, 2014
    A Modified Cysteine Knot Ligand Trap of the TGF-β Superfamily, ACE-083, Increases Muscle Mass Locally in Mice. 13th International Congress on Neuromuscular Diseases; July 7, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 19, 2014
    Modified Activin Receptor IIB Ligand Trap Mitigates Ineffective Erythropoiesis and Disease Complications in Murine Beta-Thalassemia. Blood 2014; 123(25):3864-3872
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 13, 2014
    Modified ActRIIB-Fc Fusion Protein (ACE-536) Decreases Irreversible Sickle Cells in a Murine Model of Sickle Cell Disease . European Hematology Associtation 19th Congress; June 13, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Jun 1, 2014
    Long-term Effects of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001 Phase 2A Study. 51st ERA-EDTA Congress; May 31-June 1, 2014
    + VIEW FULL Publication
  • Publication
    Dalantercept
    May 30, 2014
    Phase 2 Study of Dalantercept Monotherapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. American Society of Oncology Annual Meeting; May 30 – June 3, 2014
    + VIEW FULL Publication
  • Publication
    Dalantercept
    May 30, 2014
    A Phase 2 Randomized Study of Dalantercept Plus Axitinib Versus Placebo Plus Axitinib in Advanced Renal Cell Carcinoma: Results from the Part 1 Dose Escalation and Expansion Cohorts. American Society of Oncology Annual Meeting; May 30 – June 3, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Apr 26, 2014
    A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers. American Journal of Hematology; published online April 26, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Apr 23, 2014
    Interim Analysis of ACE-011-REN-001: The First 28 Day Dose Cycle of Low and Medium Starting Doses of Sotatercept Compared to Placebo for Correction of Anemia in Hemodialysis Subjects. Poster #81, National Kidney Foundation (NKF) 2014 Spring Clinical Meeting
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Apr 17, 2014
    Targeting a New Regulator of Erythropoiesis to Alleviate Anemia. Nature Medicine. April 2014; 20(4):334-35
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Apr 8, 2014
    Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors? Clinical Cancer Research 2014; published online April 8, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Mar 25, 2014
    Transforming Growth Factor-β Superfamily Ligand Trap ACE-536 Corrects Anemia by Promoting Late-Stage Erythropoiesis. Nature Medicine 2014; published online March 23, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 25, 2014
    An Activin IIa Ligand Trap Corrects Ineffective Erythropoiesis in β-Thalassemia. Nature Medicine 2014; published online March 23, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 21, 2014
    Sotatercept in Patients with Osteolytic Lesions of Multiple Myeloma. British Journal of Haematology 2014; published online March 21, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 18, 2014
    An Activin Receptor IIA Ligand Trap Promotes Erythropoiesis Resulting in a Rapid Induction of Red Blood Cells and Haemoglobin. British Journal of Haematology 2014; published online March 18, 2014
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jan 15, 2014
    Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor-like Kinase 1 Ligand Trap, in Patients with Advanced Cancer. Clin Cancer Research 2014;20:482-89
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 9, 2013
    A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results. Blood 2013; 122:3448
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Aug 16, 2013
    Multiple-Dose, Safety, Pharmacokinetic, Pharmacodynamic Study of Sotatercept, a Novel Erythropoietic Agent, in Healthy Postmenopausal Women. J Clin Pharmacol. 2013 Nov; 53:1121-30
    + VIEW FULL Publication
  • Publication
    ACE-031
    Jan 28, 2013
    A Single Ascending-Dose Study of Muscle Regulator ACE-031 in Healthy Volunteers. Muscle & Nerve. March 2013; 47:416-423
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 7, 2012
    Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs 2013; 22(1): 87-101
    + VIEW FULL Publication
  • Publication
    ACE-661
    Jul 3, 2012
    A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. PNAS 2012; 109(30):12207-12212
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 30, 2011
    ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011; 117(26): 6999-7006
    + VIEW FULL Publication
  • Publication
    ACE-031
    May 1, 2011
    Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse. Muscle & Nerve 2011; 43(5): 694-9
    + VIEW FULL Publication
  • Publication
    ACE-031
    Mar 1, 2011
    Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol 2011;178(3):1287-97
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 1, 2010
    Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J. Bone Miner Res 2010; 25(12): 2633-46
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Oct 1, 2010
    Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010;12(5):586-97
    + VIEW FULL Publication
  • Publication
    ACE-031
    Sep 1, 2010
    A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. Endocrinology 2010; 151(9): 4289–4300
    + VIEW FULL Publication
  • Publication
    ACE-031
    Jul 2, 2010
    Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB. J Biol Chem 2010; 285(27): 21037–21048
    + VIEW FULL Publication
  • Publication
    ACE-031
    May 13, 2010
    Administration of a Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth Independent of Fiber Type. J Appl Physiol 2010;109(3):635-42
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Apr 1, 2010
    A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46(4):1082-8
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 16, 2010
    Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. PNAS 2010, 107(11): 5124-5129
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 2, 2010
    ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Mol Cancer Ther 2010; 9(2): 379–88
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jan 1, 2010
    Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010; 207(1): 85-100
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Jan 1, 2010
    Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 2010;46(1):64-71
    + VIEW FULL Publication
  • Publication
    ACE-031
    Nov 1, 2009
    The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond). 2009; 33(11): 1265-1273
    + VIEW FULL Publication
  • Publication
    ACE-031
    Oct 28, 2009
    Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction. Am J Physiol Regul Integr Comp Physiol 298: R96–R103, 2010
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 1, 2008
    Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women. J Bone Min Res 2009;24:744–752
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 13, 2008
    A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087
    + VIEW FULL Publication